Freeze Dried Plasma in Healthy Volunteers
Conditions
Brief summary
Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
Detailed description
This is a single-site, partial double-blind study in healthy volunteers designed to assess the safety of infusing ascending doses of reconstituted autologous freeze dried plasma (FDP) in 3 fixed-dose cohorts. Beginning with Cohort 1, subjects will receive a single infusion of 1 unit (approximately 270 mL) of either FDP manufactured from fresh frozen plasma (FFP) derived from autologous whole blood (WB) collection(s) that use citrate phosphate dextrose (CPD) as the anticoagulant (FDP-CPD) or FDP manufactured from FFP units from autologous plasmapheresis where acid citrate dextrose (ACD) is used as the anticoagulant (FDP-ACD). Recruitment of subjects for Cohort 2 follows the completion of infusions in Cohort 1. Subjects in Cohort 2 will receive a single infusion of 2 units (approximately 540 mL) of either FDP-CPD or FDP-ACD before recruitment for Cohort 3 is initiated. Subjects enrolled in Cohort 3 will receive the highest study dose, a plasma infusion dose of 3 units (approximately 810 mL) of FDP-ACD at one infusion visit and the same dose of autologous FFP at another infusion visit. Cohort 3 subjects will only be infused with FDP and FFP products sourced from autologous plasmapheresis. Randomization of Cohort 3 subjects to a treatment sequence determines whether they will be infused with 3 units of FDP or 3 units of FFP at their first infusion visit followed by infusion with the alternate product at the second infusion visit. A 2-week interval will be maintained between infusion visits in Cohort 3. Crossover of FDP and FFP enables comparison of infusion safety and select coagulation factor recoveries within the same subjects between FDP and FFP at this higher dose.
Interventions
BIOLOGICALAutologous Freeze Dried Plasma (FDP)
Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
BIOLOGICALFresh Frozen Plasma (FFP)
Controlled FFP in cohort 3 only
Sponsors
U.S. Army Medical Research and Development Command
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and non-pregnant/non-breastfeeding females; * Minimum weight is 140 pounds, maximum weight is 220 pounds; * Ages 18-55 years; * Self-reports that he or she feels well and healthy; * Scores ≥ 35 on the Duke Activity Status Index; * Able to donate 1 unit of WB based on the AABB donor history questionnaire with modifications indicated. Subjects with history of travel which puts them at risk for Creutzfeldt-Jakob Disease (CJD) or malaria will be eligible to participate; * Has read the educational materials on donating blood and has had his or her questions answered; * Able and willing to provide written informed consent; * Available for the duration of the trial, which is approximately 12 weeks for subjects in Cohort 1 and Cohort 2, Arm 4; approximately 16 weeks for Cohort 2, Arm 3 and Cohort 3 (includes time for collections, product manufacture, and infusions), and able to come to the treatment clinic for scheduled study visits; * Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective, medically accepted contraceptive regimen. Highly effective methods of birth control are defined as those which result in a lower failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner; * All females must have a negative urine pregnancy test prior to enrollment; and * Understands the English language.
Exclusion criteria
* Known liver, kidney, cardiovascular, neurologic, gastrointestinal, blood, endocrine/metabolic, autoimmune or pulmonary disease, or treated or untreated hypertension; * Cancer of any kind, under treatment or resolved; * Known or past coagulopathy conditions; * Any conditions, medications, etc. on the AABB medical deferral list; * Past history of asthma (defined as use of a prescribed daily asthma controller medication or required asthma medication in the past 2 weeks); * Past diagnosis of stroke, deep vein thrombosis, or transient ischemic attack * Family history of venous or arterial thrombosis before the age of 50 in first-degree relatives (i.e., biological parents, full siblings, or children); * History of abnormal electrocardiogram (EKG); * Current smoker (defined as having smoked within the last 6 months); * Known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness or received a positive test result for HIV infection; * Positive test for Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) or Human T-cell Lymphotropic Virus (HTLV); * History or significant treated or untreated mental health issues; * Female subject who is pregnant, lactating, or with a positive pregnancy test; * Currently taking an antibiotic or another medication for an infection; * Treatment or use of aspirin (or other platelet inhibiting agents) within 14 days of study donation and infusion visits; * Currently using any medications for anticoagulant therapy; * Previous use of clotting factor concentrate(s); * Receipt of blood or blood products within the past 12 months; * In the past week, has had a headache and fever at the same time; * Known intolerance to any excipients (citrate) in the study drug formulation; * Systolic blood pressure greater than 140 mmHg; * Diastolic blood pressure greater than 90 mmHg; * Temperature greater than 100°F; * Known hematocrit less than 38% for both male and female donors; * Positive direct antiglobulin test (DAT); * Treatment with any investigational agent within 1 month before treatment infusion for this trial; * Participation in any phase of any other investigational trials while participating in this trial; * Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule; * Other unspecified reasons that, in the opinion of the PI, make the subject unsuitable for enrollment; or * Institutionalized because of legal or regulatory order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | Follow-up assessments on days 2, 8, 29, and telephone assessments on days 3 and 4 | Assess the safety of single infusions of FDP at increasing fixed doses of either 1 unit, 2 units, or 3 units in normal healthy subjects by evaluating vital signs during and after infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | Follow-up assessments on days 2, 8, 16, 22, 43, and telephone assessments on days 3, 4, 17, and 18 | Assess the safety and tolerability of a fixed-dose infusion of 3 FDP units in comparison to infusion with the same dose of autologous Fresh Frozen Plasma (FFP) in normal healthy subjects by evaluating vital signs and laboratory tests |
| Number of Participants With Significant Changes in Specific Coagulation Values | For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43. | Determine if the changes in specific coagulation values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. Blood thrombin, Coombs direct test, Fibrin D dimer, and Thrombin-antithrombin III levels are determined through a blood test to check if your blood is clotting normally. Positive tests or any values below or above the normal reference range is considered abnormal. |
| Number of Participants With Significant Changes in Specific Hematology Values | For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43. | Determine if the changes in specific hematology values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. The specific hematology values are determined through a blood test. Any values below or above the normal reference range is considered abnormal. |
| Number of Participants With Significant Changes in Specific Chemistry Values | For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43. | Determine if the changes in specific chemistry values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. Glucose levels and liver function levels, ALT and AST, are determined through a blood test. Any values below or above the normal reference range is considered abnormal. |
Countries
United States
Participant flow
Recruitment details
Healthy volunteers were recruited at an academic medical center between February 2017 and March 2018. The first participant was enrolled on March 6, 2017 and the last participant was enrolled on April 5, 2018.
Pre-assignment details
Of 40 screened participants, 30 met inclusion criteria and were enrolled. Six participants were withdrawn prior to receiving study treatment. Twenty four participants were infused with plasma.
Participants by arm
| Arm | Count |
|---|---|
| 1 Unit, Single Infusion FDP-CPD Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD 270 mL
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers | 4 |
| 1 Unit, Single Infusion FDP-ACD Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD 270 mL
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers | 4 |
| 2 Units, Single Infusion FDP-CPD Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD 540 mL
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers | 4 |
| 2 Units, Single Infusion FDP-ACD Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD 540 mL
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers | 4 |
| 3 Units Per Crossover Infusion FDP-ACD x FFP Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits. 810 mL each infusion
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
Fresh Frozen Plasma (FFP): Controlled FFP in cohort 3 only | 4 |
| 3 Units Per Crossover Infusion FFP x FDP-ACD Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits. 810 mL each infusion
Autologous Freeze Dried Plasma (FDP): Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
Fresh Frozen Plasma (FFP): Controlled FFP in cohort 3 only | 4 |
| Total | 24 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Technical Problems: Leak in plasma bag | 0 | 0 | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | 1 Unit, Single Infusion FDP-CPD | 1 Unit, Single Infusion FDP-ACD | 2 Units, Single Infusion FDP-CPD | Total | 2 Units, Single Infusion FDP-ACD | 3 Units Per Crossover Infusion FDP-ACD x FFP | 3 Units Per Crossover Infusion FFP x FDP-ACD |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 34.8 years STANDARD_DEVIATION 7 | 34.3 years STANDARD_DEVIATION 9.9 | 33.5 years STANDARD_DEVIATION 4.8 | 34.03 years STANDARD_DEVIATION 10.3 | 33.8 years STANDARD_DEVIATION 17.9 | 35.8 years STANDARD_DEVIATION 6.1 | 32.0 years STANDARD_DEVIATION 10.7 |
| Blood Type A | 3 Participants | 2 Participants | 3 Participants | 12 Participants | 0 Participants | 2 Participants | 2 Participants |
| Blood Type AB | 0 Participants | 1 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 1 Participants |
| Blood Type B | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants |
| Blood Type O | 0 Participants | 1 Participants | 1 Participants | 7 Participants | 2 Participants | 2 Participants | 1 Participants |
| Body Mass Index (BMI) | 27.0 kg/m^2 STANDARD_DEVIATION 4.1 | 27.4 kg/m^2 STANDARD_DEVIATION 1.3 | 26.2 kg/m^2 STANDARD_DEVIATION 4.8 | 27.25 kg/m^2 STANDARD_DEVIATION 3.57 | 26.3 kg/m^2 STANDARD_DEVIATION 4.2 | 28.8 kg/m^2 STANDARD_DEVIATION 3.6 | 27.8 kg/m^2 STANDARD_DEVIATION 2.3 |
| Childbearing Potential No | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Childbearing Potential Yes | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 4 Participants | 4 Participants | 24 Participants | 4 Participants | 4 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Height | 172.7 cm STANDARD_DEVIATION 7.5 | 185.4 cm STANDARD_DEVIATION 5.5 | 187.3 cm STANDARD_DEVIATION 8.4 | 180.97 cm STANDARD_DEVIATION 7.34 | 177.8 cm STANDARD_DEVIATION 3.6 | 180.4 cm STANDARD_DEVIATION 3.6 | 182.2 cm STANDARD_DEVIATION 11.8 |
| History of any diseases and/or surgeries No | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants |
| History of any diseases and/or surgeries Yes | 3 Participants | 4 Participants | 4 Participants | 22 Participants | 3 Participants | 4 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 4 Participants | 4 Participants | 23 Participants | 4 Participants | 4 Participants | 3 Participants |
| Region of Enrollment United States | 4 participants | 4 participants | 4 participants | 24 participants | 4 participants | 4 participants | 4 participants |
| Rh Factor Negative | 2 Participants | 0 Participants | 1 Participants | 6 Participants | 2 Participants | 1 Participants | 0 Participants |
| Rh Factor Positive | 2 Participants | 4 Participants | 3 Participants | 18 Participants | 2 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 4 Participants | 4 Participants | 21 Participants | 4 Participants | 4 Participants | 3 Participants |
| Weight | 80.2 Kg STANDARD_DEVIATION 10.3 | 94.1 Kg STANDARD_DEVIATION 7.1 | 91.6 Kg STANDARD_DEVIATION 15.2 | 89.1 Kg STANDARD_DEVIATION 10.86 | 83.1 Kg STANDARD_DEVIATION 13.4 | 93.4 Kg STANDARD_DEVIATION 8.3 | 92.2 Kg STANDARD_DEVIATION 8.9 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 |
| other Total, other adverse events | 2 / 4 | 2 / 4 | 0 / 4 | 0 / 4 | 4 / 4 | 1 / 4 |
| serious Total, serious adverse events | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 | 0 / 4 |
Outcome results
Primary
Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests
Assess the safety of single infusions of FDP at increasing fixed doses of either 1 unit, 2 units, or 3 units in normal healthy subjects by evaluating vital signs during and after infusion
Time frame: Follow-up assessments on days 2, 8, 29, and telephone assessments on days 3 and 4
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 1 Unit, Single Infusion FDP-CPD | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
| 1 Unit, Single Infusion FDP-ACD | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
| 2 Units, Single Infusion FDP-CPD | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
| 2 Units, Single Infusion FDP-ACD | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests | 4 Participants |
Secondary
Number of Participants With Significant Changes in Specific Chemistry Values
Determine if the changes in specific chemistry values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. Glucose levels and liver function levels, ALT and AST, are determined through a blood test. Any values below or above the normal reference range is considered abnormal.
Time frame: For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 0 Participants |
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 0 Participants |
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 1 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 1 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 1 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | ALT increased | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | Glucose increased | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Chemistry Values | AST increased | 0 Participants |
Secondary
Number of Participants With Significant Changes in Specific Coagulation Values
Determine if the changes in specific coagulation values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. Blood thrombin, Coombs direct test, Fibrin D dimer, and Thrombin-antithrombin III levels are determined through a blood test to check if your blood is clotting normally. Positive tests or any values below or above the normal reference range is considered abnormal.
Time frame: For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 0 Participants |
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 1 Participants |
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 0 Participants |
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 1 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 1 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Coombs direct test positive | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Fibrin D dimer increased | 1 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Thrombin-antithrombin III increased | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Coagulation Values | Blood thrombin increased | 0 Participants |
Secondary
Number of Participants With Significant Changes in Specific Hematology Values
Determine if the changes in specific hematology values are similar with clinically meaningful levels pre and post infusion in the different arm groups by evaluating laboratory tests. The specific hematology values are determined through a blood test. Any values below or above the normal reference range is considered abnormal.
Time frame: For cohorts 1 and 2, follow-up assessments on days 2, 8 and 29. For cohort 3, follow-up assessments on days 2, 8, 16, 22, and 43.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
| 2 Units, Single Infusion FDP-CPD | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
| 2 Units, Single Infusion FDP-ACD | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
| 3 Units Per Crossover Infusion FDP-ACD x FFP | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
| 3 Units Per Crossover Infusion FFP x FDP-ACD | Number of Participants With Significant Changes in Specific Hematology Values | 0 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events
Assess the safety and tolerability of a fixed-dose infusion of 3 FDP units in comparison to infusion with the same dose of autologous Fresh Frozen Plasma (FFP) in normal healthy subjects by evaluating vital signs and laboratory tests
Time frame: Follow-up assessments on days 2, 8, 16, 22, 43, and telephone assessments on days 3, 4, 17, and 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 1 Unit, Single Infusion FDP-CPD | Number of Participants With Treatment-emergent Adverse Events | 3 Participants |
| 1 Unit, Single Infusion FDP-ACD | Number of Participants With Treatment-emergent Adverse Events | 1 Participants |